;PMID: 4065181
;source_file_837.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..49] = [t:0..49]
;1)sentence:[e:55..189] = [t:55..189]
;2)section:[e:193..265] = [t:193..265]
;3)sentence:[e:269..379] = [t:269..379]
;4)sentence:[e:380..646] = [t:380..646]
;5)sentence:[e:648..899] = [t:648..899]
;6)sentence:[e:900..1131] = [t:900..1131]
;7)sentence:[e:1132..1211] = [t:1132..1211]
;8)sentence:[e:1212..1324] = [t:1212..1324]
;9)section:[e:1328..1372] = [t:1328..1371]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:1328..1372][t:1328..1371]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1371..1372] ]
;ERROR_POS mismatch [30..33] t:token e:NNP Sep

;section 0 Span:0..49
;Eur J Cancer Clin Oncol. 1985 Sep;21(9):1099-106.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..12] Cancer) (NNP:[13..17] Clin)
        (NNP:[18..23] Oncol) (.:[23..24] .) (CD:[25..29] 1985)
        (token:[30..33] Sep) (::[33..34] ;) (CD:[34..36] 21)
        (-LRB-:[36..37] -LRB-) (NNP:[37..38] 9) (-RRB-:[38..39] -RRB-)
        (::[39..40] :) (CD:[40..44] 1099) (::[44..45] -) (CD:[45..48] 106)
        (.:[48..49] .)))

;sentence 1 Span:55..189
;The role of metabolic activation by cytochrome P-450 in covalent binding of
;VP  16-213 to rat liver and HeLa cell microsomal proteins.
;[91..107]:cyp450:"cytochrome P-450"
;[131..141]:substance:"VP  16-213"
;[180..188]:substance:"proteins"
(SENT
  (NP-HLN
    (NP
      (NP (DT:[55..58] The) (NN:[59..63] role))
      (PP (IN:[64..66] of)
        (NP
          (NP (JJ:[67..76] metabolic) (NN:[77..87] activation))
          (PP (IN:[88..90] by)
            (NP (NN:[91..101] cytochrome) (NN:[102..107] P-450))))))
    (PP (IN:[108..110] in)
      (NP
        (NP (JJ:[111..119] covalent) (NN:[120..127] binding))
        (PP (IN:[128..130] of)
          (NP (NN:[131..133] VP) (NN:[135..141] 16-213)))
        (PP (TO:[142..144] to)
          (NP
            (NP
              (NML (NN:[145..148] rat) (NN:[149..154] liver))
              (NML-1 (-NONE-:[154..154] *P*)))
            (CC:[155..158] and)
            (NP
              (NML (NN:[159..163] HeLa) (NN:[164..168] cell))
              (NML-1 (JJ:[169..179] microsomal) (NNS:[180..188] proteins)))))))
    (.:[188..189] .)))

;section 2 Span:193..265
;van Maanen JM, de Ruiter C, de Vries J, Kootstra PR, Gobas F, Pinedo HM.
(SEC
  (FRAG (NNP:[193..196] van) (NNP:[197..203] Maanen) (NNP:[204..206] JM)
        (,:[206..207] ,) (IN:[208..210] de) (NNP:[211..217] Ruiter)
        (NNP:[218..219] C) (,:[219..220] ,) (NNP:[221..223] de)
        (NNP:[224..229] Vries) (NNP:[230..231] J) (,:[231..232] ,)
        (NNP:[233..241] Kootstra) (NNP:[242..244] PR) (,:[244..245] ,)
        (NNP:[246..251] Gobas) (NNP:[252..253] F) (,:[253..254] ,)
        (NNP:[255..261] Pinedo) (NNP:[262..264] HM) (.:[264..265] .)))

;sentence 3 Span:269..379
;Covalent binding of 3H-labeled VP 16-213 to rat liver and HeLa cell
;microsomal  proteins was studied in vitro.
;[289..291]:substance:"3H"
;[300..309]:substance:"VP 16-213"
;[349..357]:substance:"proteins"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[269..277] Covalent) (NN:[278..285] binding))
      (PP (IN:[286..288] of)
        (NP
          (ADJP (NN:[289..291] 3H) (HYPH:[291..292] -) (JJ:[292..299] labeled))
           (NN:[300..302] VP) (NN:[303..309] 16-213)))
      (PP (TO:[310..312] to)
        (NP
          (NP
            (NML (NN:[313..316] rat) (NN:[317..322] liver))
            (NML-1 (-NONE-:[322..322] *P*)))
          (CC:[323..326] and)
          (NP
            (NML (NN:[327..331] HeLa) (NN:[332..336] cell))
            (NML-1 (JJ:[337..347] microsomal) (NNS:[349..357] proteins))))))
    (VP (VBD:[358..361] was)
      (VP (VBN:[362..369] studied)
        (NP-2 (-NONE-:[369..369] *))
        (ADVP (FW:[370..372] in) (FW:[373..378] vitro))))
    (.:[378..379] .)))

;sentence 4 Span:380..646
;Metabolic activation by cytochrome P-450 was  found to play a role in the
;covalent binding of VP 16-213 to rat liver  microsomal proteins, as shown by
;the need of NADPH cofactor, the increased  binding after phenobarbital
;pretreatment and the inhibition by SFK-525A.
;[404..420]:cyp450:"cytochrome P-450"
;[474..483]:substance:"VP 16-213"
;[509..517]:substance:"proteins"
;[543..557]:substance:"NADPH cofactor"
;[588..601]:substance:"phenobarbital"
;[637..645]:substance:"SFK-525A"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[380..389] Metabolic) (NN:[390..400] activation))
      (PP (IN:[401..403] by)
        (NP (NN:[404..414] cytochrome) (NN:[415..420] P-450))))
    (VP (VBD:[421..424] was)
      (VP (VBN:[426..431] found)
        (S
          (NP-SBJ-1 (-NONE-:[431..431] *))
          (VP (TO:[432..434] to)
            (VP (VB:[435..439] play)
              (NP (DT:[440..441] a) (NN:[442..446] role))
              (PP (IN:[447..449] in)
                (NP
                  (NP (DT:[450..453] the) (JJ:[454..462] covalent)
                      (NN:[463..470] binding))
                  (PP (IN:[471..473] of)
                    (NP
                      (NP (NN:[474..476] VP) (NN:[477..483] 16-213))
                      (PP (TO:[484..486] to)
                        (NP
                          (NML (NN:[487..490] rat) (NN:[491..496] liver))
                          (JJ:[498..508] microsomal) (NNS:[509..517] proteins))))))))))
        (,:[517..518] ,)
        (SBAR-ADV (IN:[519..521] as)
          (S
            (NP-SBJ-2 (-NONE-:[521..521] *))
            (VP (VBN:[522..527] shown)
              (NP-2 (-NONE-:[527..527] *))
              (PP (IN:[528..530] by)
                (NP
                  (NP
                    (NP (DT:[531..534] the) (NN:[535..539] need))
                    (PP (IN:[540..542] of)
                      (NP (NN:[543..548] NADPH) (NN:[549..557] cofactor))))
                  (,:[557..558] ,)
                  (NP
                    (NP (DT:[559..562] the) (JJ:[563..572] increased)
                        (NN:[574..581] binding))
                    (PP (IN:[582..587] after)
                      (NP (NN:[588..601] phenobarbital)
                          (NN:[602..614] pretreatment))))
                  (CC:[615..618] and)
                  (NP
                    (NP (DT:[619..622] the) (NN:[623..633] inhibition))
                    (PP (IN:[634..636] by)
                      (NP (NN:[637..645] SFK-525A)))))))))))
    (.:[645..646] .)))

;sentence 5 Span:648..899
;Addition of ascorbic acid or alpha-phenyl-N-tert. butylnitrone to the
;incubation  mixture depressed covalent binding by about 85%, suggesting that
;formation of a  reactive metabolite from the phenolic structure may be
;involved in the binding  process.
;[660..673]:substance:"ascorbic acid"
;[677..710]:substance:"alpha-phenyl-N-tert. butylnitrone"
;[774..777]:quantitative-value:"85%"
;[820..830]:substance:"metabolite"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[648..656] Addition))
      (PP (IN:[657..659] of)
        (NP
          (NP (JJ:[660..668] ascorbic) (NN:[669..673] acid))
          (CC:[674..676] or)
          (NP (NN:[677..696] alpha-phenyl-N-tert) (.:[696..697] .)
              (NN:[698..710] butylnitrone))))
      (PP (TO:[711..713] to)
        (NP (DT:[714..717] the) (NN:[718..728] incubation)
            (NN:[730..737] mixture))))
    (VP (VBD:[738..747] depressed)
      (NP (JJ:[748..756] covalent) (NN:[757..764] binding))
      (PP-EXT (IN:[765..767] by)
        (NP
          (QP (IN:[768..773] about) (CD:[774..776] 85))
          (NN:[776..777] %)))
      (,:[777..778] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[778..778] *))
        (VP (VBG:[779..789] suggesting)
          (SBAR (IN:[790..794] that)
            (S
              (NP-SBJ-1
                (NP (NN:[795..804] formation))
                (PP (IN:[805..807] of)
                  (NP (DT:[808..809] a) (JJ:[811..819] reactive)
                      (NN:[820..830] metabolite)))
                (PP (IN:[831..835] from)
                  (NP (DT:[836..839] the) (JJ:[840..848] phenolic)
                      (NN:[849..858] structure))))
              (VP (MD:[859..862] may)
                (VP (VB:[863..865] be)
                  (VP (VBN:[866..874] involved)
                    (NP-1 (-NONE-:[874..874] *))
                    (PP-CLR (IN:[875..877] in)
                      (NP (DT:[878..881] the) (NN:[882..889] binding)
                          (NN:[891..898] process)))))))))))
    (.:[898..899] .)))

;sentence 6 Span:900..1131
;VP 16-213 did not inhibit aminopyrine N-demethylase at the  concentration
;used in the binding experiments (17 microM), indicating that  metabolism of
;its methylenedioxy group does not play a role in binding to  microsomal
;proteins.
;[900..909]:substance:"VP 16-213"
;[926..951]:substance:"aminopyrine N-demethylase"
;[1007..1009]:quantitative-value:"17"
;[1010..1016]:quantitative-units:"microM"
;[1122..1130]:substance:"proteins"
(SENT
  (S
    (NP-SBJ (NN:[900..902] VP) (NN:[903..909] 16-213))
    (VP (VBD:[910..913] did) (RB:[914..917] not)
      (VP (VB:[918..925] inhibit)
        (NP (NN:[926..937] aminopyrine) (NN:[938..951] N-demethylase))
        (PP (IN:[952..954] at)
          (NP
            (NP (DT:[955..958] the) (NN:[960..973] concentration))
            (VP (VBN:[974..978] used)
              (NP (-NONE-:[978..978] *))
              (PP (IN:[979..981] in)
                (NP (DT:[982..985] the) (NN:[986..993] binding)
                    (NNS:[994..1005] experiments))))
            (PRN (-LRB-:[1006..1007] -LRB-)
              (NP (CD:[1007..1009] 17) (NN:[1010..1016] microM))
              (-RRB-:[1016..1017] -RRB-))))
        (,:[1017..1018] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1018..1018] *))
          (VP (VBG:[1019..1029] indicating)
            (SBAR (IN:[1030..1034] that)
              (S
                (NP-SBJ
                  (NP (NN:[1036..1046] metabolism))
                  (PP (IN:[1047..1049] of)
                    (NP (PRP$:[1050..1053] its) (NN:[1054..1068] methylenedioxy)
                        (NN:[1069..1074] group))))
                (VP (VBZ:[1075..1079] does) (RB:[1080..1083] not)
                  (VP (VB:[1084..1088] play)
                    (NP (DT:[1089..1090] a) (NN:[1091..1095] role))
                    (PP (IN:[1096..1098] in)
                      (NP
                        (NP (NN:[1099..1106] binding))
                        (PP (TO:[1107..1109] to)
                          (NP (JJ:[1111..1121] microsomal)
                              (NNS:[1122..1130] proteins)))))))))))))
    (.:[1130..1131] .)))

;sentence 7 Span:1132..1211
;HeLa cell microsomes were found to possess aminopyrine  N-demethylase
;activity.
;[1175..1201]:substance:"aminopyrine  N-demethylase"
(SENT
  (S
    (NP-SBJ-1
      (NML (NN:[1132..1136] HeLa) (NN:[1137..1141] cell))
      (NNS:[1142..1152] microsomes))
    (VP (VBD:[1153..1157] were)
      (VP (VBN:[1158..1163] found)
        (S
          (NP-SBJ-1 (-NONE-:[1163..1163] *))
          (VP (TO:[1164..1166] to)
            (VP (VB:[1167..1174] possess)
              (NP
                (NML (NN:[1175..1186] aminopyrine)
                     (NN:[1188..1201] N-demethylase))
                (NN:[1202..1210] activity)))))))
    (.:[1210..1211] .)))

;sentence 8 Span:1212..1324
;Covalent binding of radiolabeled VP 16-213 to HeLa cell  microsomes decreased
;by about 64% if NADPH was omitted.
;[1245..1254]:substance:"VP 16-213"
;[1299..1302]:quantitative-value:"64%"
;[1306..1311]:substance:"NADPH"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1212..1220] Covalent) (NN:[1221..1228] binding))
      (PP (IN:[1229..1231] of)
        (NP (VBN:[1232..1244] radiolabeled)
           (NN:[1245..1247] VP) (NN:[1248..1254] 16-213)))
      (PP (TO:[1255..1257] to)
        (NP
          (NML (NN:[1258..1262] HeLa) (NN:[1263..1267] cell))
          (NNS:[1269..1279] microsomes))))
    (VP (VBD:[1280..1289] decreased)
      (PP-EXT (IN:[1290..1292] by)
        (NP
          (QP (IN:[1293..1298] about) (CD:[1299..1301] 64))
          (NN:[1301..1302] %)))
      (SBAR-ADV (IN:[1303..1305] if)
        (S
          (NP-SBJ-1 (NN:[1306..1311] NADPH))
          (VP (VBD:[1312..1315] was)
            (VP (VBN:[1316..1323] omitted)
              (NP-1 (-NONE-:[1323..1323] *)))))))
    (.:[1323..1324] .)))

;section 9 Span:1328..1371
;PMID: 4065181 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1328..1332] PMID) (::[1332..1333] :) (CD:[1334..1341] 4065181)
        (-LRB-:[1342..1343] -LSB-) (NNP:[1343..1349] PubMed) (::[1350..1351] -)
        (VBN:[1352..1359] indexed) (IN:[1360..1363] for)
        (NNP:[1364..1371] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[1371..EOF] ]

(ORPH -RSB-)
